A joint effort to give everyone the right to sight

Article

Forty five millon people are blind worldwide, yet 80% of blindness is avoidable

VISION 2020 member organisations are working together to eliminate avoidable blindness worldwide by the year 2020, in order to give everyone in the world the Right to Sight. As one corporate member, Carl Zeiss is working to make this vision a reality by helping people help themselves.

For example, we have committed ourselves to setting up ophthalmology training centres in five different regions of the world within five years. The first one was opened in Bandung, Indonesia in 2007. To equip this centre and train staff, we provided financial resources, slit lamps, therapeutic lasers and a surgical microscope. Together with the International Agency for Prevention of Blindness, we have coordinated training programmes.

In addition to these training centres, Carl Zeiss has also successfully partnered VISION 2020 in other initiatives. These include skills development and transfer and in equipping and upgrading existing training centres, in India, Africa and other parts of the developing world.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.